BioGeneriX AG, of Mannheim, Germany, and Neose Technologies Inc., of Horsham, Pa., signed an agreement to use Neose's GlycoPEGylation technology to develop a longacting, next-generation version of granulocyte-colony stimulating factor (G-CSF).(Other News To Note)

* BioGeneriX AG, of Mannheim, Germany, and Neose Technologies Inc., of Horsham, Pa., signed an agreement to use Neose's GlycoPEGylation technology to develop a longacting, next-generation version of granulocyte-colony stimulating factor (G-CSF). They will share preclinical expenses, and BioGeneriX will fund the clinical development program. Neose, which is receiving an up-front fee, will have commercial rights in the U.S., Canada, …